Table 2.

Demographic and clinical characteristics of patients with A. baumannii infection.

	Total (%) N = 81	Fatal (%) N = 67	Survived (%) N = 14	p-value
Period
Pre-Pandemic, 27 Months (January 2018–March 2020)	27 (33.33)	22 (32.84)	5 (35.71)	0.835
Pandemic, 27 Months (April 2020–June 2022)	54 (66.67)	45 (67.16)	9 (64.28)	0.835
Demographic characteristics
Median Age (IQR)	70 (61–79)	69 (59–79)	70 (64–77)	0.685
Female Gender	48 (59.3)	39 (58.2)	9 (64.3)	0.674
Inflammatory markers
Median Procalcitonin (IQR)	3.56 (1.08–22.81)	4.00 (1.08–25.13)	1.91 (1.08–4.63)	0.183
Median CRP (IQR)	213.6 (140.9–329.5)	214.3 (150.3–301.6)	174.4 (98.3–364.0)	0.861
Clinical characteristics
Mechanical ventilation	77 (95.06)	66 (98.51)	11 (78.57)	0.002
COVID-19	38 (46.91)	34 (50.75)	4 (28.57)	0.223
Fever > 38 °C	47 (58.02)	37 (55.22)	10 (71.43)	0.264
Comorbidity	66 (81.48)	54 (80.60)	12 (85.71)	0.654
Median Apache Score (IQR)	20 (15–27)	19.5 (15–24)	27 (20–30)	0.204
Malignancy	36 (44.44)	30 (44.78)	6 (42.86)	0.895
Healthcare associated	51 (62.96)	40 (59.70)	11 (78.57)	0.184
Infection site
Tracheal aspirate	69 (85.18)	61 (91.04)	8 (57.14)	0.001
Blood	24 (29.63)	17 (25.37)	7 (50.00)	0.066
Urine	1 (1.23)	1 (1.49)	0	N/A
Antimicrobial resistance
Amikacin resistance	65 (80.25)	55 (82.09)	10 (71.43)	0.362
Gentamicin resistance	65 (80.25)	55 (82.09)	10 (71.43)	0.362
Meropenem resistance	73 (90.12)	62 (83.78)	11 (78.57)	0.111
Imipenem resistance	73 (90.12)	62 (83.78)	11 (78.57)	0.111
Ceftazidime resistance	74 (91.36)	62 (83.78)	12 (85.71)	0.409
Piperacillin/Tazobactam resistance	74 (91.36)	62 (83.78)	12 (85.71)	0.409
Ciprofloxacin resistance	73 (90.12)	62 (83.78)	11 (78.57)	0.067
Colistin resistance	0	0	0	N/A

Significant values are in [bold].